MedPath

The search for biomarkers to enable detection and monitoring of disease progression from NAFLD to NASH and NASH itself; the Amsterdam NASH cohort

Conditions
AFLD, NASH
Registration Number
NL-OMON19935
Lead Sponsor
Academic Medical Center (AMC), Amsterdam
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
Not specified
Target Recruitment
1100
Inclusion Criteria

•Diagnosis of steatosis hepatis on ultrasound or by biopsy

•>18 years of age

Exclusion Criteria

•Abusive alcohol use (>20 IU/week)

•Hepatitis B and/or C

Study & Design

Study Type
Observational non invasive
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
to identify and validate noninvasive diagnostic methods (imaging and molecular markers) in disease progression from NAFLD to NASH as well as progression of NASH itself
Secondary Outcome Measures
NameTimeMethod
to apply a systems biology approach to identify the hierarchy of driving mechanisms (microbial and metabolic markers) involved in the conversion of NAFLD-NASH and NASH-cirrhosis after 5 years
© Copyright 2025. All Rights Reserved by MedPath